Filing Details

Accession Number:
0001571049-14-000510
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-02-19 16:16:10
Reporting Period:
2014-02-14
Filing Date:
2014-02-19
Accepted Time:
2014-02-19 16:16:10
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1338095 Nephrogenex Inc. NRX Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1362743 J Richard Markham C/o Nephrogenex, Inc.
79 T.w. Alexander Drive
Research Triangle Park NC 27709
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-02-14 2,148,365 $0.00 2,148,365 No 4 C Indirect See footnote
Common Stock Acquisiton 2014-02-14 890,140 $0.00 3,038,505 No 4 C Indirect See footnote
Common Stock Acquisiton 2014-02-14 412,592 $0.00 3,451,097 No 4 A Indirect See footnote
Common Stock Acquisiton 2014-02-14 790,000 $12.00 4,241,097 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect See footnote
No 4 C Indirect See footnote
No 4 A Indirect See footnote
No 4 P Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2014-02-14 13,964,398 $0.00 2,148,365 $0.00
Series A Preferred Stock 8% Convertible Promissory Note Disposition 2014-02-14 0 $0.00 5,785,962 $0.00
Common Stock Series A Preferred Stock Acquisiton 2014-02-14 5,785,962 $0.00 890,140 $0.00
Common Stock Series A Preferred Stock Disposition 2014-02-14 5,785,962 $0.00 890,140 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 2014-04-01 No 4 C Indirect
5,785,962 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. The issuer's Series A Preferred Stock automatically converted into shares of Common Stock on a 1-for-6.5 basis upon the closing of the issuer's initial public offering and had no expiration date.
  2. Consists of 2,113,077 shares held by Care Capital Investments III LP and 35,288 shares held by Care Capital Offshore Investments III L.P.
  3. Care Capital III LLC is the general partner of Care Capital Investments III LP and Care Capital Offshore Investments III LP (collectively, "Care Capital") and as a result, Care Capital III LLC has the ultimate power to vote or direct the vote and to dispose or direct the disposition of such shares. The reporting person, Jan Leschly, Jerry N. Karabelas and David R. Ramsay are the four managing members at Care Capital III LLC, and in their capacity as such, may be deemed to exercise shared voting and investment power over the shares held by Care Capital. The reporting person is a managing member of Care Capital III LLC, and serves as a representative of Care Capital on the issuer's board of directors. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
  4. Consists of 875,523 shares held by Care Capital Investments III LP and 14,617 shares held by Care Capital Offshore Investments III L.P.
  5. Care Capital Investments III LP and Care Capital Offshore Investments III LP, together with certain other investors (collectively, the "Investors"), entered into an Omnibus Agreement and Consent with the issuer pursuant to which the Investors agreed to cancel certain contingent rights held by the Investors to purchase additional shares of the issuer's Series A preferred stock in the future at the original Series A preferred stock price. Pursuant to this agreement, an aggregate of 593,590 shares of the issuer's common stock were issued to the Investors concurrently with the completion of the IPO, in return for cancelling such contingent rights, of which Care Capital Investments III LP received 405,815 shares of Common Stock and Care Capital Offshore Investments III LP received 6,777 shares of Common Stock.
  6. The transactions contemplated by the Omnibus Agreement and Consent were approved by the issuer's board of directors for purposes of the exemption afforded by Rule 16b-3 promulgated under the Securities Exchange Act of 1934.
  7. Consists of 777,024 shares held by Care Capital Investments III LP and 12,976 shares held by Care Capital Offshore Investments III L.P.
  8. The issuer's 8% Convertible Promissory Notes (the "Notes") automatically converted into a number of shares of Series A Preferred Stock equal to the quotient of the aggregate outstanding principal amount and all accrued and unpaid interest due under the Notes divided by $1.11083. Such shares of Series A Preferred Stock then automatically converted into shares of Common Stock on a 1-for-6.5 basis upon the closing of the issuer's initial public offering.
  9. Consists of $6,321,656 of Notes convertible into 5,690,925 shares of Series A Preferred Stock held by Care Capital Investments III, LP and $105,575 of Notes convertible into 95,037 shares of Series A Preferred Stock held by Care Capital Offshore Investments III, L.P.